Jason Mouabbi, Assistant Professor at MD Anderson Cancer Center, shared a post on X:
“SABCS25 Recap 1 | HER2CLIMB-05
HER2CLIMB-05 showed that adding tucatinib to maintenance HP after 4–6 cycles of THP improved mPFS to ~24 months in mHER2+ BC.
Here is my take:
- HR+ subgroup I would still favor PATINA (HP + ET + palbociclib) for maintenance:
PATINA: mPFS ~45 months (∆ +15 vs HP)
HC-05 (HR+): mPFS ~25 months (∆ ~7 vs HP)
Post-DB09 reality With DESTINYBreast09 moving SoC toward T-DXd + pertuzumab, maintenance only makes sense if it’s less toxic than induction.
HC-05 reported ~43% grade ≥3 AEs high, in my view.”
More posts from SABCS 2025.
